Hebert, A.; Glaab, D.; Schreiber, R. A Phase 1 Open -Label Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Calcipotriene Foam, 0.005% Applied Under Maximal Use Conditions in Adolescent Subjects With Plaque Psoriasis. J of Skin 2019, 3, 171.